Dyne Therapeutics (DYN) Change in Accured Expenses (2019 - 2026)

Dyne Therapeutics' Change in Accured Expenses history runs 8 years deep, the most recent figure standing at -$4.8 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 44.15% year-over-year to -$4.8 million; the TTM figure through Mar 2026 stood at $12.0 million (up 7.55% YoY), while the FY2025 annual figure was $8.3 million, up 192.14% from the prior year.
• Change in Accured Expenses was -$4.8 million for Q1 2026 at Dyne Therapeutics, up from -$9.5 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $21.4 million in Q4 2023 to a low of -$28.8 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged $954529.4 across 5 years, with a median of -$991000.0 in 2024.
• The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses jumped 917.29% in 2023, then tumbled 854.89% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at $4.6 million in 2022, then surged by 360.85% to $21.4 million in 2023, then plunged by 104.63% to -$991000.0 in 2024, then sank by 854.89% to -$9.5 million in 2025, then jumped by 49.23% to -$4.8 million in 2026.
• The last three Change in Accured Expenses figures came in at -$4.8 million (Q1 2026), -$9.5 million (Q4 2025), and $18.5 million (Q3 2025), per Business Quant data.